Suchen
Beigene Ltd
ONCZur Watchlist hinzufügen
289.990USD
+10.100+3.61%
Handelsschluss 06/29, 16:00（ET）Kurse um 15 Minuten verzögert
29.51BMarktkapitalisierung
62.12KGV TTM
mehr Informationen über Beigene Ltd Unternehmen
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Beigene Ltd Informationen
BörsenkürzelONC
Name des UnternehmensBeOne Medicines AG
IPO-datumMar 02, 2016
CEOOyler (John Victor)
Anzahl der mitarbeiter11000
WertpapierartDepository Receipt
GeschäftsjahresendeMar 02
Addressec/o BeOne Medicines I GmbH
StadtBASEL
BörseNASDAQ OMX - NASDAQ BASIC
LandSwitzerland
Postleitzahl4051
Telefon41616851900
Websitehttps://beonemedicines.com/
BörsenkürzelONC
IPO-datumMar 02, 2016
CEOOyler (John Victor)
Führungskräfte von Beigene Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
12.90K
-26.88%
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Eric E. Hedrick, M.D.
Dr. Eric E. Hedrick, M.D.
Interim Chief Medical Officer, Immuno-Oncology
Interim Chief Medical Officer, Immuno-Oncology
--
--
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
12.90K
-26.88%
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Beigene Ltd?
Die fünf größten Anteilseigner von Beigene Ltd sind: Dr. Xiaobin Wu, Ph.D.
Wie viele Institutionen halten Anteile an Beigene Ltd (ONC)?
Mit Stand vom 2026Q1 halten 602 Institutionen Anteile an Beigene Ltd, mit einem Gesamtmarktwert von etwa 40.42M, was 36.84% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1961186.00 gestiegen.
Was ist die größte Einnahmequelle von Beigene Ltd?
Am 2026Q1 erzielte das Geschäft mit Product für Beigene Ltd den höchsten Umsatz in Höhe von 1.37B, was 97.35% des Gesamtumsatzes entspricht.
